Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial
- Details
- Category: AstraZeneca
New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of dual antiplatelet therapy, Brilinta (ticagrelor) monotherapy (90mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases
- Details
- Category: Bayer
Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to research new drug candidates to treat chronic lung diseases. The joint lab will host scientists from all three parties and Bayer is investing more than USD 30 million to fund joint research projects over the next five years.
AstraZeneca amends collaboration with Ironwood for Linzess in China
- Details
- Category: AstraZeneca
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).
Educational campaign helps teens and their caregivers tackle the everyday challenges of living with moderate-to-severe atopic dermatitis
- Details
- Category: Sanofi
Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. Sanofi and Regeneron, in partnership with the National Eczema Association (NEA), today launched the next phase of Understand AD, a disease awareness initiative focused on educating people about moderate-to-severe AD.
FDA grants Fast Track designation for Farxiga in heart failure
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS).
More Pharma News ...
- Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack
- Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
- Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound
- Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
- Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
- Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
- Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients